Novo Nordisk A/S (NVO.N)

NVO.N on New York Stock Exchange

44.36USD
20 Nov 2014
Price Change (% chg)

$-0.38 (-0.85%)
Prev Close
$44.74
Open
$44.35
Day's High
$44.53
Day's Low
$44.25
Volume
58,230
Avg. Vol
202,886
52-wk High
$49.10
52-wk Low
$34.30

NVO.N

Chart for NVO.N

About

Novo Nordisk A/S is a healthcare company. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. It is engaged in diabetes care. It has a range of diabetes product portfolio, including a portfolio of modern insulins and the first human once-daily GLP-1 analog. In addition,... (more)

Overall

Beta: 0.94
Market Cap (Mil.): $94,102.83
Shares Outstanding (Mil.): 2,112.56
Dividend: 0.83
Yield (%): 1.86

Financials

  NVO.N Industry Sector
P/E (TTM): 27.21 38.20 39.19
EPS (TTM): 1.64 -- --
ROI: 65.79 17.90 17.21
ROE: 71.98 18.65 18.13
Search Stocks

BRIEF-Nine out of 10 lost weight with Novo's obesity drug -study

Nov 4 - Novo Nordisk A/S says: * New phase 3a data demonstrate that nine out of 10 adults with obesity lost

04 Nov 2014

BRIEF-Novo Nordisk invests $130 mln in diabetes research in Denmark

* Invests 750 million Danish crowns in new laboratories for diabetes research in Denmark (around $130 million)

31 Oct 2014

UPDATE 3-Novo Nordisk reassures on 2015 outlook after Sanofi jolt

* Shares up almost 4 percent (Adds analysts, details on Tresiba, updates shares)

30 Oct 2014

Novo Nordisk more cautious on timing of U.S. Tresiba launch

COPENHAGEN - Novo Nordisk is more cautious in its assessment of when it would launch its Tresiba diabetes drug in the United States, a critical growth driver for the future, according to statements it made in its quarterly report.

30 Oct 2014

Novo Nordisk more cautious on timing of U.S. Tresiba launch

COPENHAGEN, Oct 30 - Novo Nordisk is more cautious in its assessment of when it would launch its Tresiba diabetes drug in the United States, a critical growth driver for the future, according to statements it made in its quarterly report.

30 Oct 2014

Novo Nordisk says will update on possible NNIT IPO in Jan

COPENHAGEN - Denmark's Novo Nordisk said on Thursday that it would provide an update on whether or not to list its IT subsidiary NNIT on January 30, when it provides its next earnings report.

30 Oct 2014

Novo Nordisk says will update on possible NNIT IPO in Jan

COPENHAGEN, Oct 30 - Denmark's Novo Nordisk said on Thursday that it would provide an update on whether or not to list its IT subsidiary NNIT on January 30, when it provides its next earnings report.

30 Oct 2014

Novo Nordisk says U.S. market always competitive, seen no recent change

COPENHAGEN, Oct 30 - Danish drug producer Novo Nordisk said on Thursday it saw no change in the pricing environment of the U.S. diabetes market, which it has always seen as competitive.

30 Oct 2014

NORDIC STOCKS - Factors to watch on Oct 30

HELSINKI, Oct 30 - The following stocks may be affected by newspaper reports and other factors on Thursday:

30 Oct 2014

RPT-Novo Nordisk sees 10 pct EBIT growth in 2015

COPENHAGEN, Oct 30 - Denmark's Novo Nordisk forecast 10 percent growth in operating profit in local currencies next year, the same as this year although sales in 2014 are now expected to come in slightly lower, the company said on Thursday.

30 Oct 2014

Competitors

  Price Change
Sanofi SA (SASY.PA) €75.02 -1.81
Eli Lilly and Co (LLY.N) $66.80 -0.41

Earnings vs. Estimates

Search Stocks